Vermillion Inc. (VRML)

0.55
0.03 5.15
NASDAQ : Health Technology
Prev Close 0.58
Open 0.59
Day Low/High 0.52 / 0.61
52 Wk Low/High 0.27 / 1.57
Volume 354.06K
Avg Volume 231.00K
Exchange NASDAQ
Shares Outstanding 97.19M
Market Cap 56.63M
EPS -0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Vermillion To Report Second Quarter 2019 Financial Results On August 8

Vermillion To Report Second Quarter 2019 Financial Results On August 8

AUSTIN, Texas, July 31, 2019 (GLOBE NEWSWIRE) -- Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women's health company focused on gynecologic disease, today announced that it will report financial results for the three and six months ended June...

Vermillion Announces Publication Of New Study Demonstrating Overa's Greater Sensitivity In Detecting Ovarian Cancer Compared With ROMA, HE4 CA125, And CA125 Alone

Vermillion Announces Publication Of New Study Demonstrating Overa's Greater Sensitivity In Detecting Ovarian Cancer Compared With ROMA, HE4 CA125, And CA125 Alone

Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women's health company focused on gynecologic disease, today announced publication of a paper entitled: "Clinical Performance Comparison of Two In-Vitro Diagnostic Multivariate Index Assays (IVDMIAs)...

This Labor Day Weekend, Talk to Every Woman You Know About Ovarian Cancer

This Labor Day Weekend, Talk to Every Woman You Know About Ovarian Cancer

The biggest challenge to ovarian cancer diagnostic care is awareness, according to Valerie Palimeri, CEO of Vermillion.

Vermillion Announces Publication Of First OVA1® Clinical Utility Study

Vermillion Announces Publication Of First OVA1® Clinical Utility Study

Nearly all of the patients who had primary ovarian malignancies were appropriately referred to gynecologic oncologists, highlighting the clinical utility of OVA1

Vermillion Receives $2 Million Disbursement Of Up To $4 Million Loan From The Connecticut Department Of Economic And Community Development

Vermillion Receives $2 Million Disbursement Of Up To $4 Million Loan From The Connecticut Department Of Economic And Community Development

Proceeds from Low Interest Loan to be Primarily Utilized to Fund Build-Out of Vermillion's Trumbull, CT Facility Including Investment in Laboratory and Information Technology Infrastructure

6 Oil Stocks to Watch as Oil Remains Volatile

6 Oil Stocks to Watch as Oil Remains Volatile

Oil prices remain volatile, and investors should remain cautious when investing in the sector. Here are 6 stocks recommended by BMO Capital Markets.

3 Stocks Boosting The Drugs Industry Higher

3 Stocks Boosting The Drugs Industry Higher

TheStreet highlights 3 stocks that pushed the Drugs industry

3 Stocks Pushing The Drugs Industry Lower

3 Stocks Pushing The Drugs Industry Lower

TheStreet highlights 3 stocks pushing the Drugs industry lower today.

3 Stocks Raising The Drugs Industry Higher

3 Stocks Raising The Drugs Industry Higher

TheStreet highlights 3 stocks that pushed the Drugs industry

3 Drugs Stocks Driving The Industry Higher

3 Drugs Stocks Driving The Industry Higher

TheStreet highlights 3 stocks that pushed the Drugs industry

3 Drugs Stocks Pushing The Industry Higher

3 Drugs Stocks Pushing The Industry Higher

TheStreet highlights 3 stocks that pushed the Drugs industry

3 Stocks Pushing The Drugs Industry Lower

3 Stocks Pushing The Drugs Industry Lower

TheStreet highlights 3 stocks pushing the Drugs industry lower today.

3 Stocks Driving The Drugs Industry Higher

3 Stocks Driving The Drugs Industry Higher

TheStreet highlights 3 stocks that pushed the Drugs industry

Faruqi & Faruqi, LLP Launches An Investigation Against Vermillion, Inc. (VRML) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors

Faruqi & Faruqi, LLP Launches An Investigation Against Vermillion, Inc. (VRML) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors

Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Vermillion, Inc.

4 Stocks Under $10 Spiking Higher

4 Stocks Under $10 Spiking Higher

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

4 Stocks Under $10 Moving Higher

4 Stocks Under $10 Moving Higher

Keep these under-$10 stocks on your radar.

Vermillion Management Discusses Q2 2012 Results - Earnings Call Transcript

Vermillion Management Discusses Q2 2012 Results - Earnings Call Transcript

Vermillion Management Discusses Q2 2012 Results - Earnings Call Transcript

7 Stocks Under $10 Soaring Higher

7 Stocks Under $10 Soaring Higher

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

7 Stocks Soaring in a Weak Market

7 Stocks Soaring in a Weak Market

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

8 Stocks Under $10 Making Big Moves

8 Stocks Under $10 Making Big Moves

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

7 Stocks Under $10 Moving Higher

7 Stocks Under $10 Moving Higher

These under-$10 stocks are making huge-percentage moves to the upside today.

5 Drug Stock Losers of 2010

5 Drug Stock Losers of 2010

Clinical trial failures, poor sales and crushing debt pummeled shares of Vermillion, Oxigene and Angiotech in 2010.

Best and Worst Drug Stocks in Q3

KV Pharmaceuticals was the best-performing biotech and drug stock in the third quarter, while Icagen was the worst.

Biotech Stock Mailbag - 2Q Updates

Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.

TheStreet Quant Rating: D- (Sell)